ALKEM LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,884 INR | -0.55% |
|
+2.90% | -6.13% |
| 04-16 | Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak | CI |
| 03-28 | Alkem Laboratories Forms Subsidiary for Medical Devices Business | MT |
| Sales 2024 * | 129B 1.55B 124B | Sales 2025 * | 142B 1.7B 136B | Capitalization | 587B 7.04B 562B |
|---|---|---|---|---|---|
| Net income 2024 * | 18.67B 224M 17.86B | Net income 2025 * | 21.7B 260M 20.76B | EV / Sales 2024 * | 4.39 x |
| Net cash position 2024 * | 20.12B 241M 19.25B | Net cash position 2025 * | 27.86B 334M 26.65B | EV / Sales 2025 * | 3.93 x |
| P/E ratio 2024 * |
32.1
x | P/E ratio 2025 * |
27.2
x | Employees | 16,871 |
| Yield 2024 * |
0.88% | Yield 2025 * |
0.99% | Free-Float | 36.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkem Laboratories Limited
More recommendations
More press releases
| 1 day | -0.55% | ||
| 1 week | +2.90% | ||
| Current month | -1.18% | ||
| 1 month | -2.51% | ||
| 3 months | -1.85% | ||
| 6 months | +32.28% | ||
| Current year | -6.13% |
1 week
4 665.00
5 020.00
1 month
4 567.055 095.00
Current year
4 567.055 520.00
1 year
3 186.305 520.00
3 years
2 712.305 520.00
5 years
1 660.005 520.00
10 years
1 152.505 520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vikas Gupta
CEO | Chief Executive Officer | - | 21/09/23 |
Nitin Agrawal
DFI | Director of Finance/CFO | - | 01-31 |
Manish Narang
CMP | Compliance Officer | 54 | 31/10/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | - | |
| Chief Executive Officer | 84 | 08/08/73 | |
Sudha Ravi
BRD | Director/Board Member | 68 | 28/06/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 6 M€ | +6.07% | - | |
| 0.01% | 31 M€ | +3.50% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4,884 | -0.55% | 140 520 |
| 26/04/24 | 4,910 | +0.88% | 160,192 |
| 25/04/24 | 4,868 | +3.11% | 150,059 |
| 24/04/24 | 4,721 | +0.35% | 55,269 |
| 23/04/24 | 4,704 | -0.87% | 145,622 |
Delayed Quote NSE India S.E., April 29, 2024 at 12:40 pm
More quotes
Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Companyâs product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
4,910
INR
Average target price
5,184
INR
Spread / Average Target
+5.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.13% | 7.04B | |
| +25.83% | 661B | |
| +26.86% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.78% | 231B | |
| +5.23% | 200B | |
| -8.75% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ALKEM Stock
